Natco Pharma launches Pomalidomide capsules with Breckenridge Pharmaceutical

04 Mar 2026 Evaluate

Natco Pharma, along with its partner Breckenridge Pharmaceutical, has launched Pomalidomide Capsules, a generic version of Pomalyst by Celgene in the U.S. market. Pomalidomide capsules, a thalidomide analogue, is indicated for the treatment of adult patients with?multiple myeloma?who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. 

It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma. The product is available in?1mg, 2mg, 3mg, and 4mg strengths and is distributed primarily through specialty pharmacies and clinics.

Pomalidomide Capsules, 1mg, 2mg, 3mg and 4mg, had estimated sales of $3.2 billion in the U.S. for 12 months ending September 2025 as per industry sales data. 

Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).


Natco Pharma Share Price

1001.85 49.05 (5.15%)
05-Mar-2026 15:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.65
Dr. Reddys Lab 1313.00
Cipla 1324.50
Zydus Lifesciences 915.45
Lupin 2332.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×